New drug MT-501 takes first step: safety check in healthy volunteers
NCT ID NCT06762457
First seen Dec 29, 2025 · Last updated May 19, 2026 · Updated 20 times
Summary
This early-stage study tested a new oral drug, MT-501, in 72 healthy adults aged 19 to 55. The main goal was to see if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored for side effects and changes in lab results. Since this is a first-in-human trial, it focuses on safety rather than treating any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mirador Clinical Department
San Diego, California, 92121, United States
Conditions
Explore the condition pages connected to this study.